Posts Tagged ‘Bilski’

Patents4Life is Four Years Old

Tuesday, March 26th, 2013

On March 24th, Patents4Life forgot to celebrate its 4th anniversary. On March 24, 2009, I started the blog (or is it “blawg”) by posting three articles on fairly recent Fed. Cir. decisions. One of the articles discussed the application of the then-recent “Bilski test” to the claims in suit in Classen v. Biogen (2008 WL 5273107) which involved a method of developing improved immunization schedules. The summary affirmance of the district court’s decision was based on the “machine or transformation test” developed in Bilski. Since at least one of the claims recited immunizing subjects, I wrote:

“The Bilski standard, now being applied in the area of biomedical technology, poses a significant threat to the viability of patents claiming diagnostic methods.”

(more…)

Top Ten Biotech IP Stories of 2012

Friday, December 28th, 2012

I admit, I am a sucker for lists, esp. Top Ten Lists, and a few days ago, sat through a half hour of “local news” wherein the anchors breathlessly related the Top Ten Rhode Island News Stories of 2012. Well, readers, you deserve no less that my Top Ten List of IP “Stories” that broke, sometimes over us, in 2012. So that this post is not endless, I will write it from very abbreviated notes and leave it to you to dig the details out of the patents4life archives – or to just back up through the posts of 2012. Also, past Prometheus and Myriad, the list does not mean to prioritize the events reported.

(more…)

Re-Election of Obama Keeps Patent Law and Policy on Track

Wednesday, November 7th, 2012

At least Director Kappos does not have to clean out his desk. The re-election of President Obama gives him another four years of job security – if he and his hard-working staff don’t burn out first. No matter what you think of the AIA, Director Kappos has done a remarkable job of proposing implementing regulations for its many new procedures. Apart from issuing rules by the bushel, he has been “tasked” with opening three new satellite offices. He has begun to develop guidance in non-AIA areas such as patenting diagnostic assays post-Prometheus. The defeat of President Obama might well have caused a return to the Rogan years of a “know nothing” [about patent law] Commissioner.

A President Romney surely would have supported repeal of “Obamacare”. No matter what you think of the more controversial parts of the law, it also contains the outline of procedures to approve generic biologicals, a way to cut healthcare costs that is long overdue. At least the players can continue to move forward, and not be put into limbo or returned to the starting line to run a race with new rules.

(more…)

“APPLICATION DENIED”- PROMETHEUS IN ACTION

Monday, July 30th, 2012

A mathematical equation, even directed toward solving a particular problem, cannot be patented. Prometheus (“Mayo”) 132 S. Ct. at 1299. However, in Diehr, the S. Ct. stated, hopefully, that “[a]n application of a law of nature or a mathematical algorithm to a known structure or process may well be deserving of patent protection.” Diehr, 450 U.S. at 1987. Post-Mayo, we have seen precious few examples. In a recent Bd App decision, Ex parte Potts, App. No. 2011-004700 (July 18, 2012), the Board entered a new ground of rejection, patent-ineligibility under 101, to send the application back to the Examiner. The main claims did sound broad, and involved preparing a self-organizing map (SOM) – by topographical data mining (?) from outcomes of previously treated  patients, generating a similar SOM for the patient – insofar as possible – and comparing them to predict whether or not the patient would respond  to a given treatment.

(more…)